Months into the pandemic, more companies are entering the final stages of vaccine testing.
For example, Novavax (NVAX) said it would start its Phase 3 trial among 30,000 people in the UK. In addition, a trial of 30,000 could begin in the U.S. if regulators are pleased with the safest of a Phase 2 trial under way at the moment, according to Barron’s.
The latest study in the UK will track whether adults receiving a two-dose vaccine see a lower rate of symptomatic COVID, as compared to those...
Already a member? Login below, or click here to register now for free.